Open AccessReal-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama
Author(s) -
Franklin Castillero,
Omar Castillo-Fernández,
Maria Lim-Law,
Cristiane Martin Palacios,
Lilian Montano,
Stephanie Benitez,
Jaime Samudio
Publication year - 2021
Publication title -
breast cancer management
Language(s) - English
Resource type - Journals
eISSN - 1758-1931
pISSN - 1758-1923
DOI - 10.2217/bmt-2021-0003
Subject(s) - pertuzumab , trastuzumab , medicine , breast cancer , oncology , pathological , immunohistochemistry , blockade , neoadjuvant therapy , retrospective cohort study , chemotherapy , cancer , receptor
The aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods: This was a descriptive, retrospective, real-world study. Results: Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion: Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival.